Merit Medical has acquired Biolife Delaware in a merger transaction, under which Biolife became a wholly-owned Merit subsidiary. Biolife is based in Sarasota, Fla. and manufactures patented hemostatic devices under the names StatSeal and WoundSeal.

The deal was made so Merit can offer more products to standardize, simplify, and minimize post-procedure care and maintenance. Many of Merit’s products operate through small openings in the skin that need efficient solutions to stop bleeding, help recovery, and minimize complications.

StatSeal works with the patient’s blood to quickly create a protective seal over the procedure site. It aims to complement percutaneous procedures including interventional radiology and cardiology, dialysis, electrophysiology, biopsy, and drainage.

“We are excited to enhance the portfolio of hemostatic solutions offered to clinicians with the acquisition of Biolife,” said Fred P. Lampropoulos, Merit’s chairman and CEO. “The acquisition provides effective, differentiated, hemostatic solutions for all percutaneous devices with a broad range of clinical applications including vascular closure and indwelling catheter bleeding complications. BioLife’s StatSeal and WoundSeal products address an estimated $350M global market opportunity, are clinically validated, and will enhance our ability to deliver comprehensive solutions to our customers. Moreover, with Merit’s resources and expertise, we believe we are well positioned to further develop and expand the reach of these product lines, ultimately benefiting patients and healthcare providers globally.”

The transaction’s aggregate consideration—paid in cash and assumption of Biolife liabilities—was about $120 million.

“We have updated our full-year 2025 financial guidance to include the projected impact of this acquisition from the merger effective date of May 20, 2025 to December 31, 2025 and we have reaffirmed our updated full-year 2025 financial guidance previously issued on April 24, 2025,” Lampropoulos said. “While we anticipate the transaction will be slightly dilutive to our full-year 2025 non-GAAP profitability given the partial-year contribution, we believe the financial profile of this acquisition is very attractive and is consistent with our goal of delivering sustainable, constant currency growth, improving profitability and strong free cash flow generation. We look forward to discussing this acquisition in further detail on our second quarter earnings report on July 30, 2025.”

Last fall, the company acquired Cook Medical’s lead management portfolio for about $210 million.